International
The Morning Science

What science found today

‹
 

Research

Brepocitinib yields improvements in cutaneous sarcoidosis

Medical Xpress ·

Brepocitinib yields improvements in cutaneous sarcoidosis

The Brief

  • A study in JAMA Dermatology reports that brepocitinib is associated with dose-dependent, clinically meaningful improvements in cutaneous sarcoidosis.
  • The study was published online to coincide with the annual meeting of the American College of Rheumatology.

Why it matters

The findings offer a trial-based signal that an investigational drug may improve skin manifestations of sarcoidosis, which matters to clinicians and researchers working on inflammatory skin and systemic disease.

Who’s affected

  • dermatologists and rheumatologists
  • patients with cutaneous sarcoidosis

For patients with cutaneous sarcoidosis (CS), brepocitinib is associated with dose-dependent and clinically meaningful improvements, according to a study published online in JAMA Dermatology to coincide with the annual meeting of the American College of Rheumatology, held from…

How do you feel about this?

0 Comments

    Brepocitinib yields improvements in cutaneous sarcoidosis – The Morning Science